See more : CRA International, Inc. (CRAI) Income Statement Analysis – Financial Results
Complete financial analysis of Parallax Health Sciences, Inc. (PRLX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Parallax Health Sciences, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Nippon Paper Industries Co., Ltd. (3863.T) Income Statement Analysis – Financial Results
- Yotta Acquisition Corporation (YOTAW) Income Statement Analysis – Financial Results
- Guild Holdings Company (GHLD) Income Statement Analysis – Financial Results
- Turkiye Garanti Bankasi A.S. (TKGBF) Income Statement Analysis – Financial Results
- Atlas Copco AB (ACO1.F) Income Statement Analysis – Financial Results
Parallax Health Sciences, Inc. (PRLX)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
About Parallax Health Sciences, Inc.
Parallax Health Sciences, Inc. builds and expands an integrated digital healthcare network with products and services that provide remote communication, diagnosis, treatment, and monitoring of patients. The company offers remote healthcare products, including patent pending software and mobile apps, and other services, as well as electronic kits and devices from third-party licensed platforms that are designated towards a patient's primary health concern, such as diabetes, blood pressure, cardiovascular, general monitoring, etc.; and audio and video options that interface with the patient's healthcare providers. It also provides prescription medication dosage monitoring services; and behavioral health products comprising REBOOT, a proprietary behavioral health technology for an individual or an organization to transform the cost of treating and managing chronic illnesses that include pulmonary-COPD-asthma, diabetes, and cardiovascular diseases by effecting the modification of behavior in patients being treated for these chronic diseases. In addition, the company offers diagnostics products, which comprise Target System, a proprietary POC diagnostic immunoassay testing platform; and test cartridges for the areas of infectious diseases, cardiac markers, drugs of abuse, and various other medical conditions, as well as VT-1000 desktop analyzers, target antigen detection systems, and other products. Further, it provides SPARKS Mobile, a target system hand-held analyzer; COMPASS for behavioral modification; Fotodigm platform for remote patient monitoring, telehealth, and POC diagnostic testing services; and Intrinsic Code technology for actionable insights to behavior modification. The company was formerly known as Endeavor Power Corporation and changed its name to Parallax Health Sciences, Inc. in January 2014. Parallax Health Sciences, Inc. was founded in 2005 and is headquartered in Santa Monica, California.
| Metric | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 128.60K | 11.74K | 3.20M | 23.14M | 11.58M | 0.00 | 0.00 | 0.00 | 192.25K | 20.40K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 16.83K | 20.34K | 3.23M | 19.09M | 9.87M | 0.00 | 0.00 | 0.00 | 90.09K | 36.05K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 111.77K | -8.60K | -31.10K | 4.05M | 1.71M | 0.00 | 0.00 | 0.00 | 102.16K | -15.65K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 86.92% | -73.26% | -0.97% | 17.49% | 14.73% | 0.00% | 0.00% | 0.00% | 53.14% | -76.72% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.13M | 6.43M | 6.43M | 0.00 | 1.91M | 858.66K | 473.40K | 482.57K | 2.02M | 1.06M | 4.32M | 105.57K | 0.00 | 0.00 |
| Selling & Marketing | 255.51K | 0.00 | 660.40K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.38M | 6.43M | 7.09M | 0.00 | 1.91M | 858.66K | 473.40K | 482.57K | 2.02M | 1.06M | 4.32M | 105.57K | 0.00 | 0.00 |
| Other Expenses | 120.97K | 120.62K | 0.00 | 6.27M | 1.06M | 0.00 | 0.00 | 0.00 | 0.00 | 653.00 | 0.00 | 0.00 | 74.84K | 24.73K |
| Operating Expenses | 6.51M | 6.55M | 7.09M | 6.27M | 2.97M | 858.66K | 473.40K | 482.57K | 2.02M | 1.06M | 4.32M | 105.57K | 74.84K | 24.73K |
| Cost & Expenses | 6.52M | 6.57M | 10.31M | 25.36M | 12.84M | 858.66K | 473.40K | 482.57K | 2.11M | 1.10M | 4.32M | 105.57K | 74.84K | 24.73K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 924.00 | 0.00 |
| Interest Expense | 582.51K | 1.21M | 1.31M | 908.71K | 213.92K | 246.55K | 20.55K | 11.18K | 49.31K | 759.39K | 167.09K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 187.38K | 120.62K | 345.49K | 210.99K | 77.91K | 7.99K | 12.23K | 18.55K | 4.50K | 653.00 | -609.72K | -5.98M | 924.00 | 0.00 |
| EBITDA | -12.10M | 17.62M | -12.22M | -7.11M | -3.13M | -858.66K | -471.71K | -524.94K | -1.91M | -4.37M | -4.93M | -6.08M | -73.92K | -24.73K |
| EBITDA Ratio | -9,406.25% | 150,123.60% | -382.55% | -30.74% | -27.01% | 0.00% | 0.00% | 0.00% | -995.33% | -21,424.21% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -6.39M | -6.56M | -7.12M | -2.22M | -1.26M | -858.66K | -473.40K | -482.57K | -1.92M | -1.08M | -4.32M | -105.57K | -74.84K | -24.73K |
| Operating Income Ratio | -4,971.76% | -55,893.12% | -222.79% | -9.61% | -10.90% | 0.00% | 0.00% | 0.00% | -997.67% | -5,287.06% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.47M | 23.68M | -6.76M | -6.01M | -2.46M | -254.54K | -31.09K | -72.10K | 0.00 | -3.29M | -609.72K | -5.98M | 0.00 | 0.00 |
| Income Before Tax | -12.87M | 17.11M | -13.88M | -8.23M | -3.72M | -1.11M | -504.49K | -554.67K | 0.00 | -4.37M | -4.93M | -6.08M | 0.00 | 0.00 |
| Income Before Tax Ratio | -10,004.92% | 145,785.14% | -434.30% | -35.58% | -32.12% | 0.00% | 0.00% | 0.00% | 0.00% | -21,427.42% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -5.89M | 24.89M | -5.45M | -5.10M | -2.24M | -7.99K | -10.54K | -60.92K | 49.31K | -2.53M | 167.09K | 0.00 | -924.00 | 24.73K |
| Net Income | -12.87M | 16.29M | -13.88M | -8.23M | -3.42M | -1.11M | -504.49K | -554.67K | -1.97M | -5.13M | -5.09M | -6.08M | -73.92K | -24.73K |
| Net Income Ratio | -10,004.92% | 138,762.42% | -434.30% | -35.58% | -29.53% | 0.00% | 0.00% | 0.00% | -1,023.32% | -25,150.45% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.05 | 0.08 | -0.12 | -0.07 | -0.03 | -0.01 | 0.00 | -0.01 | -0.02 | -0.12 | -7.60 | -9.31 | -0.14 | -0.93 |
| EPS Diluted | -0.05 | 0.08 | -0.08 | -0.07 | -0.03 | -0.01 | 0.00 | -0.01 | -0.02 | -0.12 | -7.60 | -9.31 | -0.14 | -0.93 |
| Weighted Avg Shares Out | 261.53M | 215.58M | 120.49M | 113.69M | 131.73M | 127.49M | 150.70M | 107.72M | 102.20M | 41.10M | 670.35K | 653.45K | 536.46K | 26.62K |
| Weighted Avg Shares Out (Dil) | 261.53M | 215.58M | 172.35M | 113.69M | 131.73M | 127.49M | 150.70M | 107.72M | 102.20M | 41.10M | 670.35K | 653.45K | 536.46K | 26.62K |
Source: https://incomestatements.info
Category: Stock Reports